Poly ICLC: all 54 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active SurveillanceRecruitingNCT06343077Phase 2
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingNCT05098210Phase 1
• ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBMActive, not recruitingNCT05283109Phase 1Results posted
• A Phase II Trial of Poly-ICLC for Low-Grade GliomasTerminatedNCT04544007Phase 2Results posted
• Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsCompletedNCT03835533Phase 1Results posted
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT03358719Phase 1Results posted
• Pembrolizumab + Poly-ICLC in MRP Colon CancerCompletedNCT02834052Phase 1/2Results posted
• Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma MultiformeCompletedNCT02078648Phase 1/2Results posted
• Enhancement by Poly-ICLC During HIV-1 InfectionCompletedNCT02071095Phase 1/2Results posted
• Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)TerminatedNCT01984892Phase 2Results posted
• A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaCompletedNCT01970358Phase 1Results posted
• Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LCTerminatedNCT01437605Phase 2Results posted
• Combination Immunotherapy and Autologous Stem Cell Transplantation for MyelomaCompletedNCT01245673Phase 2Results posted
• A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade GliomasCompletedNCT01188096Phase 2Results posted
• PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive TreatmentCompletedNCT00694551Not applicableResults posted
• Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBMCompletedNCT00262730Phase 2Results posted
• Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic GliomaCompletedNCT00058123Phase 2Results posted
• Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeTerminatedNCT00052715Phase 2Results posted
• Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLCWithdrawnNCT06064279Phase 1/2
• A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma PatientsStatus unknownNCT05281926Phase 1
• Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to SurgeryCompletedNCT05111353Phase 1
• Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerActive, not recruitingNCT05013216Phase 1
• Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal CancerWithdrawnNCT04799431Phase 1
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedNCT04116320Phase 1
• Vaccination With Flt3L, Radiation, and Poly-ICLCCompletedNCT03789097Phase 1/2
• Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing GlioblastomaCompletedNCT03665545Phase 1/2
• Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat GlioblastomaActive, not recruitingNCT03223103Phase 1
• The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian CancerTerminatedNCT03162562Phase 1
• Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain TumorsWithdrawnNCT03068832Phase 1
• A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsWithdrawnNCT02661100Phase 1/2
• PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCCCompletedNCT02544880Phase 1
• Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed GlioblastomaTerminatedNCT02510950Phase 1
• Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyWithdrawnNCT02427581Phase 1
• In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®CompletedNCT02423863Phase 2
• A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedNCT02413827Phase 1/2
• GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma PatientsCompletedNCT02149225Phase 1
• Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell LymphomaTerminatedNCT02061449Phase 1
• In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose RadiotherapyCompletedNCT01976585Phase 1/2
• Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in GlioblastomaCompletedNCT01920191Phase 1/2
• Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete RemissionCompletedNCT01842139Phase 1
• Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic CellsTerminatedNCT01783431Phase 1
• A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic AdenocarcinomaCompletedNCT01677962Phase 1
• Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast CancerTerminatedNCT01532960Phase 1
• Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy VolunteersCompletedNCT01299662Phase 1
• Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and SarcomaCompletedNCT01241162Phase 1
• A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric GliomasCompletedNCT01130077Phase 1
• DCVax Plus Poly ICLC in Healthy VolunteersCompletedNCT01127464Phase 1
• Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy VolunteersCompletedNCT01012700Phase 1
• MUC1 Vaccine for Triple-negative Breast CancerCompletedNCT00986609Early Phase 1
• Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell LymphomaTerminatedNCT00880867Phase 1
• HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II GliomasCompletedNCT00874861Early Phase 1
• Poly-ICLC to Prevent Respiratory Viral Infections A Safety StudyCompletedNCT00646152Phase 1
• Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver CancerStatus unknownNCT00553683Phase 1/2
• Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial NeoplasiaStatus unknownNCT00493545Phase 1

← Poly ICLC overview